EDAP TMS SA (EDAP) ADS Each Reprenting 1 Ord Share

Sell:$1.79Buy:$2.60$0.02 (0.81%)

NASDAQ:1.35%
Market closed | Prices delayed by at least 15 minutes
Sell:$1.79
Buy:$2.60
Change:$0.02 (0.81%)
Market closed | Prices delayed by at least 15 minutes
Sell:$1.79
Buy:$2.60
Change:$0.02 (0.81%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

Key people

Marc Oczachowski
Chairman of the Board
Ryan Rhodes
Chief Executive Officer, Director
Ken Mobeck
Global Chief Financial Officer
Francois Dietsch
Global Chief Accounting Officer
Pierre Beysson
Independent Director
Marie-Helene Meynadier
Independent Director
Fran Schulz
Independent Director
Lance Willsey
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    France
  • Sector
    Healthcare
  • Industry
    Medical Equipment & Supplies
  • ISIN
    US2683111072
  • Market cap
    $91.65m
  • Employees
    307
  • Shares in issue
    37.37m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.